 Home > Biochemistry News > Biotechnology News > Significantly improve symptoms in Parkinson's disease patients with new mechanism therapy Phase 2 clinical results are positive

Significantly improve symptoms in Parkinson's disease patients with new mechanism therapy Phase 2 clinical results are positive

 Last Update: 2022-04-20
 Source: Internet
 Author: User

Tags

cyclobenzaprine drug class

drug classification list

new directions aromatics

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Cerevance announced that its potential "first-in-class" oral Parkinson's disease investigational therapy CVN424 has achieved positive results in a Phase 2 clinical trial

Cerevance's drug discovery platform is based on a new technology called NETSseq, which can label and collect specific disease-related cell types from patient brain tissue, and then perform transcriptome and epigenetic analysis on them to discover based on this knowledge New targets for the treatment of central nervous system diseases

▲NETSseq technology platform (Image source: Cerevance's official website)

In this randomized, double-blind, placebo-controlled Phase 2 clinical trial, approximately 135 Parkinson's disease patients received two different doses of CVN424

Trial results showed that after 4 weeks of treatment, high-dose CVN424 improved the "OFF" period by 1.

References:

[1] Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson's Disease Drug Working Through a New Mechanism.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express significantly improves the symptoms of Parkinson's disease patients, and the phase 2 clinical results of the new mechanism therapy are positive

04-27

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Significantly improve symptoms in Parkinson's disease patients with new mechanism therapy Phase 2 clinical results are positive

Related Articles

Express significantly improves the symptoms of Parkinson's disease patients, and the phase 2 clinical results of the new mechanism therapy are positive